rss
Br J Ophthalmol 2009;93:986 doi:10.1136/bjo.2008.156208
  • Mailbox
    • PostScript

Promise and potential pitfalls of anti-VEGF drugs in retinopathy of prematurity

  1. B A Darlow1,
  2. C Gilbert2,
  3. G E Quinn3,
  4. R Azad4,
  5. A L Ells5,
  6. A Fielder6,
  7. A Zin7
  1. 1
    Department of Paediatrics,University of Otago, Christchurch. Christchurch, New Zealand
  2. 2
    International Centre for Eye Health, London School of Hygiene and Tropical Medicine, London, UK
  3. 3
    The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
  4. 4
    Dr Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi, India
  5. 5
    Calgary Retina Consultants, Calgary, Alberta, Canada
  6. 6
    Department of Optometry & Visual Science, City University, London, UK
  7. 7
    Instituto Fernandes Figuera, FIOCRUZ, Rio de Janeiro, Brazil
  1. Professor B Darlow, Christchurch School of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand; brian.darlow{at}otago.ac.nz
  • Accepted 20 December 2008

Only rarely does a new treatment offer a real sea change. An example in the field of neonatology is the use of exogenous surfactant for hyaline membrane disease.1 For the eye, anti-vascular endothelial growth factor (VEGF) drugs may be the therapeutic advance of our time, revolutionising the treatment of vasoproliferative retinopathies including age-related macular degeneration and diabetic retinopathy. In his informative editorial, Sears suggests that anti-VEGF therapy may play a similar role in retinopathy of prematurity.2

Retinopathy of prematurity (ROP) is a vasoproliferative disease, and it is therefore not surprising that there is increasing enthusiasm for anti-VEGF drugs.3 4 …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.